Off-Label Topical Application of Sirolimus (Rapamycin) for Dermatological Conditions

Area of Science:

• Dermatology
• Pharmacology
• Oncology

Background:

• Topical sirolimus (rapamycin), a mammalian target of rapamycin inhibitor, is approved for angiofibromas in tuberous sclerosis.
• Off-label applications of topical sirolimus are increasingly explored for diverse dermatological conditions.
• Understanding the efficacy and safety of these off-label uses is crucial for clinical practice.

Purpose of the Study:

• To review the current literature on the off-label efficacy and safety of topical sirolimus for various dermatological conditions.
• To focus on conditions beyond its approved indication, excluding lymphatic malformations but including post-laser therapies for vascular lesions.

Main Methods:

• Literature review of studies investigating topical sirolimus for dermatological conditions.
• Analysis of efficacy, safety, and adverse effects reported in published research.
• Exclusion of specific conditions (e.g., lymphatic malformations) to maintain focus.

Main Results:

• Topical sirolimus demonstrated significant efficacy in treating genetic and benign proliferative skin disorders like pachyonychia congenita, trichilemmomas, trichoepitheliomas, and Kaposi sarcoma.
• The treatment generally exhibited a favorable safety profile with minimal systemic absorption.
• Variability in formulations, dosing, and small study sizes currently limit definitive conclusions.

Conclusions:

• Topical sirolimus is a promising therapeutic option for several off-label dermatological conditions, particularly genetic and benign proliferative disorders.
• A generally good safety profile supports its use, but standardization of treatment is needed.
• Further large-scale, standardized research is warranted to validate these findings and optimize treatment protocols.